FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Translational Oncology"
DOI: 10.1016/j.tranon.2021.101244
Abstract: Introduction FLT3-ITD mutations occur in approximately 25% of patients with acute myeloid leukemia (AML) and are associated with poor prognosis. Despite initial efficacy, short duration of response and high relapse rates limit clinical use of… read more here.
Keywords: apg 2575; itd mutant; hqp1351; flt3 itd ... See more keywords